Exchange Traded Concepts LLC Sells 134 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Exchange Traded Concepts LLC trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,847 shares of the company’s stock after selling 134 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Medpace were worth $946,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Stone House Investment Management LLC purchased a new position in Medpace in the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new stake in shares of Medpace in the 3rd quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the 3rd quarter worth approximately $46,000. True Wealth Design LLC increased its position in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in Medpace by 191.4% during the 3rd quarter. UMB Bank n.a. now owns 271 shares of the company’s stock valued at $90,000 after buying an additional 178 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Trading Down 1.3 %

Shares of NASDAQ:MEDP opened at $345.81 on Wednesday. The company has a market capitalization of $10.75 billion, a PE ratio of 30.28, a P/E/G ratio of 1.77 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The business’s fifty day simple moving average is $341.16 and its 200-day simple moving average is $354.14.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Truist Financial cut their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.